Pfizer updates trial results for Aromasin in switch & upfront settings
Tuesday, December 15, 2009 15:00 IST San Antonio
Pfizer announced results from an exploratory analysis of the Intergroup Exemestane Study (IES) at a median follow-up of 91 months in estrogen-receptor positive (ER+)